Top Section/Ad
Top Section/Ad
Most recent
Offer came as markets recovered and volatility fell
Abbott Laboratories plundered $20bn as it led a trio of drug companies which printed jumbo bonds as a deluge of supply in the dollar market ensured a red-hot end to the month.
Eight banks provided loan facility to company
More articles/Ad
More articles/Ad
More articles
-
Biopharmaceutical company HutchMed (China) kicked off the roadshow for its HK$4.68bn ($602.7m) Hong Kong IPO on Friday, placing more than half of the shares in its third listing with cornerstone investors. -
Shanghai Junshi Biosciences has raised HK$2.56bn ($330.5m) in equity capital from a placement of shares that drew a solid response from investors both during wall-crossing and bookbuilding.
-
There was little let-up in demand for property companies' bonds on Tuesday, as investors stocked up on Inmobilaria Colonial and debut issuer Sirius Real Estate, before the void of issuance expected from the tail end of this week.
-
Europe’s equity capital markets bankers are expressing concern that deals they’re working on now will be damaged if the re-opening of the continent’s economies is reversed in the autumn. But new research on Covid-19 and last year’s pattern of infections shows they’re right to be nervous.
-
LinkDoc Technology, a cancer-focused medical data company, has filed paperwork for a $100m offering of American depository shares (ADS).
-
A group of Suriname’s bondholders on Monday followed through on their threat to cancel the payment relief that they had offered the sovereign, effectively pushing the government into technical default. But the move only supports expectations that restructuring negotiations will be lengthy and fraught.
